Najat Khan, Chief Commercial Officer at The Janssen Pharmaceutical Companies and board member at Recursion, shared a post on LinkedIn:
“I’m thrilled to announce that Dr. Vicki Goodman will join Recursion as our new Chief Medical Officer starting April 6.
As we continue to advance our pipeline and prepare for key milestones, Vicki brings exactly the expertise and perspective we need for this next phase. Vicki brings a highly differentiated and well-rounded perspective across drug development, regulatory strategy, and organizational leadership.
She began her career as a Medical Officer at the U.S. FDA and has since held senior leadership roles across biotech and large pharma, including Merck, Bristol Myers Squibb, and GSK, where she contributed to the development and advancement of leading oncology therapies such as KEYTRUDA, OPDIVO, TAFINLAR, and more.
Most recently, she served as CMO at Exelixis and Mural Oncology, where she built development organizations and advanced multi-asset portfolios.
What stands out most is her ability to translate scientific insights into well-designed, high-quality clinical programs, and to navigate complex regulatory and development decisions with clarity. That experience will be critical as we continue to advance our pipeline and deliver differentiated medicines for patients.
Welcome, Vicki – we’re excited to have you on the team!
Other articles featuring Najat Khan on OncoDaily.